# US 7,608,579 B2 · Lung volume reduction using glue compositions > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,608,579 B2 - Document ID: US7608579B2 - Status: Granted - Kind: B2 - Application number: 11/008,093 - Filed: 2004-12-08 - Published: 2005-12-22 - Granted: 2009-10-27 - Earliest claimed: 2004-06-16 - Assignees: PneumRx, Inc. - Inventors: Glen Gong; Ronald Dieck - Web page: https://patentgrep.com/patent/US7608579B2 ## CPC - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} - A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine - A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00) - A61K 38/166: {Streptokinase} - A61K 38/18: Growth factors; Growth regulators - A61K 38/38: Albumins - A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG] - A61K 38/45: Transferases (2) - A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)} - A61L 24/001: {Use of materials characterised by their function or physical properties} - A61L 24/0015: {Medicaments; Biocides} - A61L 24/06: obtained by reactions only involving carbon-to-carbon unsaturated bonds {(A61L24/043, A61L24/046 take precedence)} - A61L 24/106: {Fibrin; Fibrinogen} - A61L 2430/36: for embolization or occlusion, e.g. vaso-occlusive compositions or devices - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) ## Abstract The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema. ## Claims ### Claim 1 A method of reducing lung volume in a lung of a subject in need thereof comprising: providing a glue composition comprising a first adhering moiety connected via an amide bond linkage to a first site on a chemical linker, and a second adhering moiety which is connected via an amide bond to a second site on said chemical linker, wherein the chemical linker comprises a functional group selected from the group consisting of a carboxyl group and an amine group, and wherein said first and second adhering moieties adhere to different sites bearing elastase in a lung, and are independently selected from the group consisting of a) alpha-1 antitrypsin, b) elafin, and c) serpin; administering an effective amount of said glue composition to a localized region of damaged lung tissue of said subject; adhering said first adhering moiety to a first site bearing elastase in said localized region of damaged lung tissue of said subject; collapsing a first portion or all of said lung of said subject wherein said first portion comprises said localized region of damaged lung tissue; adhering said second adhering moiety to a second site bearing elastase in said damaged lung tissue; and re-inflating a second portion of the lung of said subject wherein said second portion does not comprise said damaged lung tissue, thereby reducing said lung volume. ### Claim 2 (depends on 1) The method as recited in claim 1 wherein said lung tissue comprises epithelial lining fluid. ### Claim 3 (depends on 1) The method as recited in claim 1 wherein said administering delivers said glue composition to a deep lung region. ### Claim 4 (depends on 1) The method as recited in claim 1 wherein said method is performed with prior identification of said damaged lung tissue. ### Claim 5 (depends on 1) The method as recited in claim 1 wherein said method does not damage epithelial cells within lung tissue. ### Claim 6 (depends on 1) The method as recited in claim 1 wherein said method damages epithelial cells within lung tissue by use of a sclerosing agent. ### Claim 7 (depends on 6) The method as recited in claim 6 wherein said sclerosing agent is at least one compound selected from doxycycline, bleomycin, minocycline, doxorubicin, cisplatin+cytarabine, mitoxantrone, Corynebacterium Parvum, streptokinase, and urokinase. ### Claim 8 (depends on 1) The method as recited in claim 1 wherein said glue composition does not comprise a polysaccharide or a carbohydrate moiety. ### Claim 9 (depends on 1) The method as recited in claim 1 wherein said composition does not comprise a mutant plasminogen activator-inhibitor type 1. ### Claim 10 (depends on 1) The method as recited in claim 1 wherein said elastase is neutrophil elastase. ### Claim 11 (depends on 1) The method as recited in claim 1 wherein said glue composition is less than 10 microns. ### Claim 12 (depends on 1) The method as recited in claim 1 wherein said glue composition is less than 5 microns. ### Claim 13 (depends on 1) The method as recited in claim 1 wherein said glue composition is less than 1 micron. ### Claim 14 (depends on 1) The method as recited in claim 1 wherein said administering is carried out via inhalation. ### Claim 15 (depends on 14) The method as recited in claim 14 wherein said inhalation is carried out via the mouth. ### Claim 16 (depends on 1) The method as recited in claim 1 wherein said administering is carried out via trans-thoracic administration. ### Claim 17 (depends on 1) The method as recited in claim 1 wherein said administering is carried out by placing a bronchoscope in a bronchi of a deep lung region. ### Claim 18 (depends on 17) The method as recited in claim 17, further comprising placing a catheter through said bronchoscope to reach a subsegmental bronchi. ### Claim 19 (depends on 18) The method as recited in claim 18 wherein said catheter comprises an expandable balloon-like structure. ### Claim 20 (depends on 1) The method as recited in claim 1 wherein said collapsing comprises use of negative pressure within the lung of said subject. ### Claim 21 (depends on 1) The method as recited in claim 1 wherein said collapsing comprises use of positive pressure not from the lung of said subject. ### Claim 22 (depends on 1) The method as recited in claim 1 wherein said subject is suffering from a pulmonary condition. ### Claim 23 (depends on 22) The method as recited in claim 22 wherein said pulmonary condition is emphysema or chronic obstructive pulmonary disease.